ADENURIC Tablets - Medsafe
ADENURIC® Tablets febuxostat 80 mg and 120 mg tablets Consumer Medicine Information What is in this leaflet This leaflet answers some common questions about ADENURIC® Tablets. It does not contain all the available information.
Download ADENURIC Tablets - Medsafe
Information
Domain:
Source:
Link to this page:
Documents from same domain
ADVANTAN Presentation Uses - Medsafe
www.medsafe.govt.nzADVANTAN® Data Sheet Page 1 of 9 ADVANTAN® Methylprednisolone aceponate 0.1% ointment/cream . Presentation 1 g cream or ointment contains 1 mg (0.1%) methylprednisolone aceponate.
LOXALATE 1. Product Name - Medsafe Home Page
www.medsafe.govt.nzPage 5of 21 at risk, such as the elderly, or patients with cirrhosis, or if used in combination with other medications which may cause hyponatraemia.
DATA SHEET 1 CLEXANE AND CLEXANE FORTE ... - …
www.medsafe.govt.nzNew Zealand Data Sheet June 2017 . clexane-clexane-forte-ccdsv13-dsv18-16jun17 Page 2 . 100 mg injection enoxaparin sodium 100mg (equivalent to …
SEPTANEST Articaine hydrochloride 4% with …
www.medsafe.govt.nzSEPTANEST Articaine hydrochloride 4% with adrenaline 1:100,000 Injection for local and regional dental anaesthesia DESCRIPTION SEPTANEST is a sterile aqueous solution that contains articaine hydrochloride 4% (40 mg/mL) with adrenaline acid tartrate in a 1:100,000 strength.
BOOSTRIX - Medsafe Home Page
www.medsafe.govt.nz1 BOOSTRIX®. Combined diphtheria, tetanus, acellular pertussis (dTpa) vaccine . CONSUMER MEDICINE INFORMATION WHAT IS IN THIS LEAFLET? This leaflet answers some of the common questions about BOOSTRIX vaccine.
NEW ZEALAND DATA SHEET - Medsafe
www.medsafe.govt.nzNEW ZEALAND DATA SHEET Cymevene ® DS 170831 2 of 26 Caution: Cymevene must only be administered by IV infusion over 1 hour, preferably via a
Edition Draft - Medsafe
www.medsafe.govt.nzPart 4, Ed Draft Page 2 of 9 Section 1: Good Manufacturing Practice Documentation 1.1. When is GMP Documentation Required? Medsafe requires evidence of Good Manufacturing Practice (GMP) compliance for
Data Sheet 1 PRODUCT NAME 2 QUALITATIVE AND …
www.medsafe.govt.nzNew Zealand Data Sheet 31 July 2017 Lantus – insulin glargine lantus-ccdsv19-dsv11-31jul17 Page 1 Data Sheet 1 PRODUCT NAME Lantus 100 IU/mL solution for injection in 10 …
NEW ZEALAND DATA SHEET MESTINON® - Medsafe
www.medsafe.govt.nzNEW ZEALAND DATA SHEET MESTINON® MESTINON Page 4 of 8 As the severity of myasthenia gravis often fluctuates considerably, particular care is required to
DATA SHEET PREDNISONE - Medsafe
www.medsafe.govt.nz• Epilepsy and/or seizure disorder • Peptic ulceration • Previous steroid myopathy • Tuberculosis • Patients with myasthenia gravis receiving anticholinesterase therapy since
Related documents
Urate (serum, plasma) - Association for Clinical ...
www.acb.org.uk© Copyright Association for Clinical Biochemistry 2012 Urate (serum, plasma) 1 Name and description of analyte 1.1. Name of analyte Urate
Urinalysis Hematuria Proteinuria - Division of Nephrology
www.columbianephrology.orgCrystals Acid Urine (pH<6) Alkaline Urine (pH>6) •Uric acid •Phosphates Rhombic prism form Triple phosphates Sodium urate Calcium phosphates Amorphous urate Amorphous phosphates
Protocol: AC (Doxorubicin/Cyclophosphamide)
www.midwesterncancercentre.ieDepartment of Medical Oncology Chemotherapy Protocols 3rd Edition 19 Protocol: Paclitaxel Indications: Breast Cancer – Adjuvant (high risk), Palliative
Protocol: Doxorubicin/Cisplatin - Mid-Western Cancer Centre
www.midwesterncancercentre.ieDepartment of Medical Oncology Chemotherapy Protocols 3rd Edition 78 Protocol: Doxorubicin/Cisplatin Indications: Osteosarcoma - neoadjuvant
Selby Abbey
www.selbyabbey.org.ukGOSPEL: Mark 11: 14-20 Now after John was arrested, Jesus came to Galilee, proclaiming the good news of God, and saying, The time is fulfilled, and the kingdom of God has come
高尿酸血症與痛風 之介紹及其藥物治療
www.taiwan-pharma.org.twthe journal of pharmacy 第24卷 第2期 繼 續 教 育 146 繼續教育 圖二 血清尿酸濃度與痛風年發生率的關係 參、痛風的簡介 一、痛風的診斷
The Chinese Medical Treatment of Gout - tcm-becker.ch
www.tcm-becker.chheat in patients suffering from liver and kidney vacuity, and it falls within the scope of impediment (bi).(Aiding Prescriptions)in its chapter on impediment says the following about the disease cause and disease mechanism: “The cause is bodily vacuity with vacuous and …
SERVICE REQUEST FORM KRYSTEXXAConnect
www.krystexxahcp.comINDICATION AND IMPORTANT SAFETY INFORMATION. INDICATIONS AND USAGE. KRYSTEXXA ® (pegloticase) is indicated for the treatment of chronic gout in adult patients who have failed to normalize serum uric acid and